Search Results for: 99

-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel Cascallό, Ph.D., appointed as General Director of Synthetic Biologics’ European Subsidiary, transitioning from Chief Operating Officer of VCN Biosciences- ROCKVILLE, Md., March 23, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified […]

-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 4:30 p.m. ET-

– Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration – – Strong cash position to support multiple inflection points for VCN-01 with the start of a Phase 2 trial in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma and a Phase 2/3 pivotal trial either as an adjunct

Follows recent announcement of planned acquisition of VCN Biosciences by Synthetic Biologics ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.’s (VCN) VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. Food

Lead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trials Designed for systemic delivery, high selectivity, and enhanced tumor access VCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMA Synthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time ROCKVILLE, Md., Dec.

Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy Adult Volunteers; Topline Data Readout Expected in Q2 2022 Enrollment Remains Ongoing in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Reports $72.1 Million of Cash on Hand to Fund Clinical Programs Through Key Milestones Beyond 2022 ROCKVILLE, Md., Nov.

— Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET — ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company

Topline Data Readout Expected in Q2 2022 Phase 1 Clinical Program Intended to Support Development of SYN-020 for Multiple Indications Including Celiac Disease, Non-Alcoholic Fatty Liver Disease, Age-Related Metabolic and Inflammatory Diseases, and Radiation Enteropathy ROCKVILLE, Md., Oct. 21, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics